Storia in 1 fonti

Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T

An experimental CAR-T called arlo-cel improved response rates in patients with relapsed and refractory multiple myeloma who had received at least four previous therapies.

Raccontata da

endpoints.news

Timeline cronologica

martedì 8 settembre 2026·endpoints.news
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T
An experimental CAR-T called arlo-cel improved response rates in patients with relapsed and refractory multiple myeloma who had received at least four previous therapies.